MDGL Madrigal Pharmaceuticals RESULTS: Q2, Q2 product REV $364.252M, Q2 Net Income $-57.939M, Q2 operating expenses $420.56M, Q2 Operating I
MDGL Madrigal Pharmaceuticals RESULTS: Q2, Q2 product REV $364.252M, Q2 Net Income $-57.939M, Q2 operating expenses $420.56M, Q2 Operating Income $-56.308M, Q2 EPS $-1.99
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.